Tirzepatide (GLP-1+GIP) 5 mg PEN

Regulatory framework — a critical distinction

GLP-1+GIP 5 mg PEN is a research reagent (Research Use Only) in a pre-reconstituted pen. The active substance belongs to the class of GLP-1R and GIPR dual agonists — the same class as tirzepatide (LY3298176), registered by Eli Lilly as the medicine Mounjaro (type 2 diabetes, FDA 2022, EMA 2022) and Zepbound (obesity, FDA 2023, EMA 2024). These two instances of the same chemical class represent two distinct regulatory frameworks — the RUO pen in the One Peptides catalogue is not the medicine Mounjaro or Zepbound and is not subject to pharmaceutical regulation. The active substance may be tirzepatide or another dual GLP-1/GIP analogue — in either case its status is RUO, not a medicine.

A GLP-1R and GIPR dual agonist represents an evolutionary step from monoagonists (semaglutide, liraglutide) toward molecules that simultaneously activate two signalling pathways of the incretin axis. The pharmacodynamic profile of the class was described by Coskun et al. (2018) in Molecular Metabolism for tirzepatide (LY3298176, Eli Lilly), and the SURPASS and SURMOUNT programmes generated the Phase III data published in NEJM. The broader context of the incretin axis is collected in the guide on GLP-1 peptides in metabolic research. The dual agonist is the most clinically advanced variant of incretin polypharmacology approved as a medicine.

In the One Peptides catalogue, the GLP-1+GIP class appears within a separate regulatory framework — as an RUO research reagent in a pre-reconstituted pen. The format simplifies laboratory work: no need to reconstitute a lyophilisate, with precise peptide withdrawal under controlled conditions.

What GLP-1+GIP is — a single-molecule dual-agonist peptide

GLP-1+GIP is a single peptide molecule that simultaneously activates two incretin receptors — GLP-1R and GIPR. Importantly, a dual-agonist peptide is not a mixture of two separate peptides, but a single amino-acid sequence with affinity spanning both receptors.

The best-studied representative of the class is tirzepatide (LY3298176), developed by Eli Lilly — a sequence of approximately 39 amino acids with a molecular mass of about 4813 Da. The molecule combines GIP and GLP-1 elements within a single chain, with C20 fatty-acid acylation (γ-Glu-2xOEG-C20 linker) and reversible binding to serum albumin. Albumin binding acts as a reservoir extending the half-life to about 5 days — a weekly schedule in the clinical protocols of Mounjaro and Zepbound. The full profile of this molecule is discussed in the analysis of tirzepatide — a dual GIP/GLP-1 agonist.

Chemical characteristics

Mechanism of action — why two receptors

Activation of GLP-1R triggers the profile known from semaglutide-class monoagonists: glucose-dependent insulin secretion in β cells, suppression of glucagon secretion in α cells, slowing of gastric emptying, and reduction of appetite through central action in the hypothalamic arcuate nucleus. The mechanism is glucose-dependent — under normoglycaemia, insulin secretion is not significantly stimulated.

Activation of GIPR adds a second layer: potentiation of insulin secretion in β cells, modulation of adipose-tissue metabolism, lipolysis, and regulation of energy storage. Synergistic activation of both receptors is reported in the literature as responsible for the additional metabolic effects of dual agonists relative to mono-GLP-1. The mechanism of the GLP-1 / GIP / glucagon axis is collected in the article on how incretins regulate metabolism.

In the pivotal head-to-head SURPASS-2 trial (Frías et al., NEJM 2021), tirzepatide was compared directly with semaglutide 1 mg in type 2 diabetes — the dual agonist was reported with greater reductions in HbA1c and body weight across all studied doses. The SURPASS and SURMOUNT programmes provided the Phase III data underpinning the registration of Mounjaro and Zepbound.

GLP-1+GIP PEN RUO vs Mounjaro / Zepbound — the fundamental difference

The Eli Lilly pen is a medicinal product with a package leaflet, an SmPC, and EMA pharmacovigilance oversight. The RUO pen at One Peptides is a chemical reagent with analytical documentation. Belonging to the same chemical class does not abolish the distinction between regulatory frameworks.

Position in the classification of incretin peptides

The monoagonist (semaglutide) acts solely on GLP-1R. The dual agonist (tirzepatide / the GLP-1+GIP class) adds GIPR and is the only incretin dual agonist approved as a medicine. The tri-agonist (retatrutide LY3437943) adds a third receptor — the glucagon receptor (GCGR) — and remains in Phase III of the TRIUMPH programme without registration.

Positioning of pen vs lyophilisate vial in the One Peptides catalogue

In the One Peptides catalogue, the GLP-1+GIP class appears in several variants constituting distinct SKUs: a lyophilisate vial (requires reconstitution in bacteriostatic water, full control over concentration) and a pre-reconstituted pen in two peptide contents — 5 mg (this product) and 10 mg (a higher content for protocols requiring a larger amount of reagent). The analytical quality is identical across all variants: HPLC ≥98%, MS, COA per batch, cold chain 2–8°C.

Applications in scientific research

• Incretin-axis pharmacology — receptor activity, selectivity for GLP-1R and GIPR, EC50 in cell cultures (cAMP and β-arrestin reporters).
• Animal models — DIO, ob/ob, db/db mice, Zucker rats. Endpoints: body weight, composition (DEXA, NMR), OGTT/ITT, HOMA-IR, lipid profile.
• Pharmacokinetics — PK profile of acylated analogues, albumin-binding kinetics, the influence of a C18 vs C20 chain.
• Comparative analyses — head-to-head with mono-GLP-1 (semaglutide, liraglutide), the tri-agonist (retatrutide LY3437943), and native GLP-1/GIP in SAR studies.

One Peptides quality specification

• HPLC ≥98% — the main-peak area is ≥98% of the total area sum (liquid chromatography with UV detection).
• MS confirmation — confirmation of peptide identity by molecular mass.
• COA per batch — certificate of analysis for each batch (theoretical/measured mass, HPLC profile, synthesis date, batch number).
• Cold chain 2–8°C — a refrigerated chain with monitoring from synthesis to delivery.
• Batch traceability — batch number in three places: the pen label, the invoice, and the COA.

Working with a pre-reconstituted pen in a laboratory protocol

The guide below describes the technical handling of the pen in the context of a reagent for laboratory research — it does not constitute instructions for administration in humans or animals.

Pen contents. GLP-1+GIP PEN 5 mg contains 5 mg of pre-reconstituted peptide in typically about 1.5 mL of solution (details in the batch COA).

Working with the pen. Withdraw the solution with a laboratory syringe or a microlitre-precision applicator. The solution should be clear — turbidity, sediment, or a colour change is a signal that the batch is not suitable for further work.

Working solutions. For in vitro receptor assays, the picomolar-to-nanomolar scale is standard. Prepare serial dilutions in PBS at pH 7.4 or buffers compatible with the experimental system.

Stability. Unopened pen: typically up to 24 months at 2–8°C, protected from light (details in the COA). After first opening: typically up to 28 days at 2–8°C. Avoid freeze-thaw cycles.

The peptide calculator helps convert the starting concentration in the pen to the desired working concentration. This is not a guide for administration in humans — the clinical schedules of tirzepatide in the SmPCs of Mounjaro and Zepbound apply solely to the Eli Lilly medicines.

Regulatory status — GLP-1+GIP PEN, tirzepatide, incretin-class medicines

GLP-1+GIP PEN (this product) — a Research Use Only research reagent within the chemical-reagent trade in the EU. Label: “For research use only. Not for human use”. It is not a medicinal product, a dietary supplement, or a foodstuff. It holds no EMA or FDA authorisation as a medicine.

Tirzepatide as a medicine (Eli Lilly): Mounjaro — type 2 diabetes (FDA 2022, EMA 2022); Zepbound — obesity (FDA 2023, EMA 2024). Both products are available by prescription only.

Registration landscape. Only semaglutide (mono-GLP-1, Novo Nordisk) and tirzepatide (dual GLP-1/GIP, Eli Lilly) from the incretin-peptide class hold the status of medicines registered by the EMA and FDA. Retatrutide (tri, LY3437943) and earlier experimental dual agonists remain in trade solely as RUO reagents.

WADA. Peptides from the GLP-1 and GIP agonist class are not directly listed on the current WADA Prohibited List. This status may change in subsequent editions — verifying the current guidelines rests with the researcher.

Frequently asked questions

Is GLP-1+GIP PEN the medicine Mounjaro or Zepbound?

No. GLP-1+GIP PEN is an RUO research reagent. Mounjaro and Zepbound are Eli Lilly medicines with a full EMA and FDA registration dossier, available by prescription only under physician supervision. The active substance may belong to the same chemical class (GLP-1/GIP dual agonist, in particular tirzepatide), but the RUO pen and the pharmaceutical pen originate from two distinct regulatory frameworks.

How does GLP-1+GIP PEN differ from tirzepatide in clinical trials?

The pharmacological class is the same — a GLP-1R and GIPR dual agonist. The differences concern the regulatory framework and the intended purpose. Clinical trials of tirzepatide (SURPASS, SURMOUNT) were conducted under EMA and FDA pharmacovigilance oversight with the Eli Lilly medicinal product. The RUO PEN functions as a reagent for laboratory research.

Why is the dual agonist reported more favourably than mono-GLP-1?

In the head-to-head SURPASS-2 trial, tirzepatide was compared with semaglutide 1 mg in type 2 diabetes — the dual agonist was reported with greater reductions in HbA1c and body weight across all doses. The mechanistic argument: synergistic activation of GLP-1R + GIPR produces a stronger effect on insulin secretion and adipose-tissue metabolism.

How does the 5 mg pen differ from the 5 mg lyophilisate vial?

The peptide content (5 mg) and the analytical quality (HPLC ≥98%, MS, COA) are identical. The difference is the format: the lyophilisate vial requires reconstitution in bacteriostatic water, whereas the pen is pre-reconstituted.

How long does the pen retain activity after first opening?

Typically up to 28 days at 2–8°C from the first withdrawal. Detailed stability data are in the batch COA. Avoid freeze-thaw cycles.

Are GLP-1 and GIP on the WADA list?

The current WADA Prohibited List does not directly name GLP-1 or GIP agonists as separate categories. This status may change in subsequent editions — verifying the current guidelines rests with the researcher.

Bibliography

1. Coskun T et al. (2018). LY3298176, a novel dual GIP and GLP-1 receptor agonist for type 2 diabetes (discovery to clinical proof of concept)
2. Frías JP et al. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2)
3. Min T, Bain SC (2021). The Role of Tirzepatide in the Management of Type 2 Diabetes (SURPASS Review)
4. Wilding JPH et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1)
5. Marso SP et al. (2016). Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6)

Research Use Only chemical reagent. GLP-1+GIP 5 mg PEN is not a medicinal product, a dietary supplement, or a foodstuff. It is not intended for administration to humans or animals outside a controlled experimental environment. GLP-1+GIP PEN RUO must not be confused with the Eli Lilly dual GLP-1/GIP class medicines — Mounjaro and Zepbound. The active substance may belong to the same chemical class (GLP-1/GIP dual agonist, in particular tirzepatide LY3298176), but the RUO pen and the pharmaceutical pen originate from two distinct regulatory frameworks. This information is educational and scientific in nature — it does not constitute medical advice or instructions for administration.